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Abstract 22 
Fungi and bacteria are able to persist in the human gall bladder. Previous studies have shown 23 
that bile protects C. albicans in this cryptic host niche from antifungals, providing a reservoir 24 
for re-colonization of the intestine after discontinuation of antifungal therapy. Bile and 25 
conjugated bile salts trap antifungals in micelles, thereby reducing their bioavailability and 26 
possibly promoting the development of drug resistance. Here we show that the protective 27 
effect of bile and conjugated bile salts is not limited to C. albicans, but also observed with 28 
other fungi. Interestingly, bile, but not conjugated bile salts conferred resistance of C. 29 
albicans against fluconazole. Similarly, only bile conferred resistance of Aspergillus terreus 30 
against voriconazole. To investigate this higher potency of bile in mediating antifungal 31 
protection we aimed in a step-wise reconstitution of bile from conjugated bile salts. While 32 
phospholipids and saturated fatty acids increased the ability of conjugated bile salts to protect 33 
from amphotericin B, both failed to protect from azoles. In contrast, when conjugated bile 34 
salts were supplemented with polyunsaturated fatty acids, resistance against azoles increased 35 
and the critical micelle concentration of conjugated bile salts decreased to the level of bile. 36 
We conclude that polyunsaturated fatty acids are vital in the formation of mixed micelles that 37 
exhibit a high potential to trap antifungals. Since bile-mediated protection depicts a general 38 
problem in biliary tract infections, reconstituted synthetic bile should be used to investigate 39 
drug efficacy in the biliary system. 40 
  41 
1. Introduction 42 
In liver transplant recipients biliary tract infections comprise one of the major complications 43 
that increase mortality rates and may inforce the requirement for re-transplantation (Moreno 44 
and Berenguer, 2006). About 50% of liver transplant recipients encounter at least one episode 45 
of viral, bacterial or fungal infection with Escherichia coli and Klebsiella pneumonia as the 46 
main bacterial infections followed by fungi such as Candida or Aspergillus species 47 
(Chiereghin et al., 2017). Furthermore, it has been shown that the bacterium Listeria 48 
monocytogenes freely replicates in bile implying that the gall bladder acts as a source for 49 
excretion of these bacteria (Hardy et al., 2004). In addition, gall bladder provides a reservoir 50 
for Salmonella enterica serovar Typhi even after antibiotic therapy causing severe chronic 51 
infections frequently accompanied by the development of gall stones (Gonzalez-Escobedo et 52 
al., 2011).  53 
In a murine model of disseminated candidiasis we have previously shown that Candida 54 
albicans uses the gall bladder as a cryptic reservoir under antifungal therapy (Jacobsen et al., 55 
2014). Subsequent investigations revealed that bile conferred resistance against commonly 56 
used antifungals such as the echinocandin caspofungin and the polyene macrolide 57 
amphotericin B (Jacobsen et al., 2014). As underlying mechanism of protection we found that 58 
antifungals are trapped in micelles that are formed by conjugated bile salts (Hsieh et al., 59 
2017). The resulting reduction in the bioavailability of drugs in the biliary system and 60 
possibly also in the intestine might thereby not only prevent the clearance of pathogens from 61 
these host niches, but might also lead to the development of drug resistant strains. 62 
Accordingly, a recent study revealed the emergence of echinocandin resistant Candida 63 
species in liver transplant recipients after treatment with caspofungin (Prigent et al., 2017). 64 
Resistant strains were mainly isolated from the digestive system implying that a reduced 65 
bioavailability of drugs might have caused this emergence (Prigent et al., 2017). Furthermore, 66 
case studies indicate that also other fungi and especially Aspergillus species are able to cause 67 
severe cholangitis (Erdman et al., 2002; Garcia-Ruiz et al., 1998). Therefore, it appears of 68 
high importance to clear pathogenic microorganisms residing in the biliary system. However, 69 
this requires the application of drugs that are not trapped in micelles. 70 
Antifungal protection is strictly dependent on a concentration of conjugated bile salts that is 71 
above their specific critical micelle concentration (CMC). In this respect, taurocholate 72 
displays a higher CMC value at physiological conditions than taurodeoxycholate and, 73 
accordingly, higher concentrations of taurocholate are required to confer resistance. 74 
However, while both conjugated bile salts effectively protect against caspofungin and 75 
amphotericin B, neither of both compounds protected C. albicans against the azole 76 
fluconazole (Hsieh et al., 2017). On the contrary, bile strongly reduced the in vitro sensitivity 77 
of C. albicans against fluconazole and enabled persistence in the gall bladder under 78 
fluconazole treatment in a murine model of systemic candidiasis (Jacobsen et al., 2014). 79 
Since even high concentrations of taurodeoxycholate were not able to confer fluconazole 80 
resistance this increased protective effect of bile might be linked to a lower CMC value of 81 
bile accompanied by an increased ability to trap antifungals. It has been speculated that the 82 
more complex composition of bile including fatty acids and phospholipids leads to mixed 83 
micelles that allow a more effective trapping of antifungals (Hsieh et al., 2017). 84 
To address this question, we studied the in vitro resistance of several fungal species in the 85 
presence and absence of conjugated bile salts to confirm a general mechanism of bile 86 
mediated antifungal protection. Subsequently, we analysed the effect of different fatty acid 87 
and lipid components either alone or in combination with conjugated bile salts on antifungal 88 
protection with a focus on azole resistance. 89 
  90 
2. Material and Methods 91 
2.1 Strains and culture conditions 92 
C. albicans (SC5314), S. cerevisiae (ATCC 9763) and C. neoformans (H99 and 1841) were 93 
pre-cultivated overnight in 20 ml YPD media (per litre: 10 g yeast extract, 20 g peptone, and 94 
20 g glucose) at 30°C and yeast cells were harvested by centrifugation at 4000  g. After 95 
washing cells twice in phosphate-buffered saline (PBS) cells were suspended and adjusted to 96 
selected cell densities in either YPD or MOPS-buffered RPMI 1640 medium (Sigma) 97 
containing 2% glucose (per litre: 10.4 g RPMI 1640, 34.53 g MOPS, 20 g glucose; pH 6.8; 98 
subsequently defined as RPMI medium). To obtain conidia suspension of A. fumigatus 99 
(CBS144-89) and A. terreus (SBUG844), conidia were plated on 50 mM glucose Aspergillus 100 
minimal media with nitrate as nitrogen source and 2% agar (Gressler et al., 2011). Plates 101 
were incubated at 37°C for 3-4 days (A. fumigatus) or 5-6 days (A. terreus). Conidia were 102 
harvested in 10 ml sterile PBS and filtered through a 40 μm cell-strainer. After a washing step 103 
in PBS, conidia were diluted to defined concentrations in RPMI medium and used for drug 104 
resistance analyses. 105 
 106 
2.2 Preparation of antifungals for sensitivity analyses 107 
Stock solutions of caspofungin (5 mg/ml; Cancidas, Merck, Germany) and flucytosine (10 108 
mg/ml) were prepared in PBS and filter sterilized. Stock solutions of amphotericin B (4 109 
mg/ml) and voriconazole (16 mg/ml) were prepared in DMSO. Fluconazole at 2 mg/ml was 110 
purchased from B. Braun, Germany. All drugs were diluted in the respective media used for 111 
resistance analyses. Controls were prepared according to the solvents used for stock solutions 112 
of the respective antifungals. 113 
 114 
2.3 Preparation of bile solution and lipid solubilisation in conjugated bile salt  115 
Crude porcine bile extract (Sigma, B8631) was solved in either YPD or RPMI medium to 116 
give a final concentration of 12.5% (w/v). Insoluble components were removed by 117 
centrifugation at 12000 × g. The supernatant was filter sterilised and stored at 4°C in the dark. 118 
Sodium taurodeoxycholate hydrate (Sigma, T0875) and taurocholic acid sodium salt hydrate 119 
(Sigma, T4409) were dissolved at 100 mg/ml in either YPD or RPMI medium, filtered 120 
sterilised and used as stock solutions. The following saturated fatty acids were used for 121 
preparing mixtures with conjugated bile salt: C3 (propionic acid sodium salts, Applichem, 122 
A1931), C4 (sodium butyrate, Aldrich, 303410), C8 (sodium caprylate, Fluka, 71339), C10 123 
(sodium decanoate Fluka, 21490), C14 (myristic acid sodium salt, Fluka, 70140) and C16 124 
(sodium palmitate, Fluka, 76165). Media containing 10 mg/ml taurocholate were 125 
supplemented with the indicated amounts of fatty acids. To solubilise C14 and C16, mixtures 126 
were heated to 65°C for 30-60 min. As a source of phospholipids a soy refined lecithin (Mp 127 
Biomedicals, LLC) was added at indicated concentrations. As sources of polyunsaturated 128 
fatty acids arachidonic acid (Sigma, 10931) and conjugated linolenic acid (Sigma, O5507) 129 
were used that were added to YPD or RPMI media containing 10 mg/ml sodium taurocholate. 130 
For preparation of reconstituted synthetic bile (RSB) the following components were mixed 131 
(per ml of RPMI medium): 30 mg sodium taurocholate, 30 mg sodium taurodeoxycholate, 5 132 
mg lecithin, 10 mg C14, 2.5 mg arachidonic acid and 2.5 mg conjugated linolenic acid 133 
generating an 80 mg/ml RSB stock. Stocks of an equal mixture of tauro- and 134 
taurodeoxycholate (60 mg/ml in total) or RSB lacking phospholipids and saturated fatty acids 135 
(65 mg/ml solubilised solids) were also prepared.  136 
 137 
2.4 Drug resistance analyses 138 
Antifungal drug resistance or toxicity of saturated fatty acids was tested virtually as described 139 
previously (Hsieh et al., 2017). In brief, dilutions of bile and mixtures of conjugated bile salts 140 
and lipids either with or without antifungals were prepared in either YPD or RPMI medium 141 
and transferred to 96-well plates. Fungal yeast cells or conidia were pre-diluted in the 142 
respective growth medium and added to a final concentration of 4 × 10
4
 yeasts or 1 × 10
5
 143 
conidia resulting in 200 μl supplemented medium. Plates were sealed with transparent gas 144 
permeable moisture barrier seal (4titude) and incubated at 37°C except for C. neoformans 145 
species that were incubated at 30°C. Plates were rotated every 15 min prior to interval 146 
readings of the optical density at 600 nm (OD600). Final end point measurements of plates 147 
were performed at the indicated time points. Results were either shown as OD600 readings or 148 
in percentage of residual growth when normalised against control groups without antifungal 149 
treatment. All growth tests were performed in three parallel wells with at least one 150 
independent biological replication. Data were analysed by using Microsoft Excel or 151 
GraphPad Prism software. 152 
 153 
2.5 Determination of critical micelle concentrations (CMC) and rhodamine 6G influx 154 
analyses 155 
Critical micelle concentration (CMC) was determined as described previously (Hsieh et al., 156 
2017) by measuring the change of absorbance of eosin Y at 542 nm using a microplate reader 157 
(Multiskan
TM
 Go, Thermo). Bile, conjugated bile salts and mixtures of conjugated bile salts 158 
containing different lipid compositions were tested in serial dilutions and data were analysed 159 
using Microsoft Excel software by plotting the absorbance values against the logarithmic 160 
concentration of the solubilising agent. For rhodamine 6G (R6G) influx assays C. albicans 161 
yeast cells were incubated at 30°C in RPMI medium in the presence of 1 μM R6G and 1 162 
mg/ml of either bile, conjugated bile salts or mixtures of conjugated bile salts and lipids. 163 
Aliquots of cells were harvested at different time points and washed twice in 50 mM HEPES 164 
buffer pH 7.0. R6G fluorescence was measured in a microplate reader (Fluostar Omega plate 165 
reader, BMG Labtech) at 545 nm excitation and 590 nm emission. Fluorescence was 166 
normalised against the cell density at 600 nm.  167 
 168 
2.6 Statistical analyses 169 
All bar diagrams show mean values + standard deviation (SD). All experiments were 170 
performed in biological duplicates or triplicates with three wells inoculated in parallel. 171 
Comparisons between multiple groups were analysed by one-way analysis of variance 172 
(ANOVA) followed by Tukey's multiple comparison test using GraphPad Prism (GraphPad 173 
Software). 174 
 175 
3. Results 176 
3.1 Taurocholate confers amphotericin B resistance in a variety of fungal species 177 
We first studied whether drug resistance mediated by conjugated bile salt is limited to C. 178 
albicans or depicts a general mechanism of protection in fungi against antifungals. Therefore, 179 
we selected the non-pathogenic ascomycete yeast Saccharomyces cerevisiae and its 180 
pathogenic relative Candida glabrata, the filamentous ascomycetes Aspergillus fumigatus 181 
and Aspergillus terreus as well as the basidiomycete Cryptococcus neoformans var. grubii 182 
H99 (serotype A) and C. neoformans 1841 (serotype D) for protection analyses against 183 
amphotericin B. A concentration of 25 mg/ml taurocholate was tested first for its toxicity, but 184 
was well tolerated by all strains, except for the C. neoformans isolates that revealed a slight, 185 
but significant reduction in growth rate (Fig.1). Subsequently, we determined amphotericin B 186 
concentrations that suppress growth of the respective species. S. cerevisiae and C. glabrata 187 
showed no growth at 0.5 µg/ml, the two Aspergillus species did not proliferate at 1 µg/ml and 188 
the two C. neoformans strains did not grow in the presence of 2 µg/ml of amphotericin B 189 
(Fig.1). The combination of taurocholate with the respective amphotericin B concentration 190 
restored growth of all fungal strains (Fig.1) indicating that conjugated bile salts mediate 191 
fungal protection that is not limited to C. albicans. 192 
 193 
3.2 Bile, but not its conjugated bile salts protect from azoles 194 
Next, we investigated the efficacy of bile and conjugated bile salts to protect from azoles. 195 
While a first-line treatment of C. albicans infections recommends the use of echinocandins, 196 
fluconazole is still used in clinically stable patients with no previous exposure to azoles 197 
(Calandra et al., 2016). Voriconazole is one of the azoles of choice in prophylactic and acute 198 
therapy of A. terreus infections (Karthaus, 2011; Vehreschild et al., 2007). The use of azoles 199 
in the treatment of A. terreus infections is of special importance since most A. terreus strains 200 
exhibit a natural resistance against amphotericin B (MIC ≥ 1 mg/l), although the molecular 201 
basis for this is not yet well understood (Pastor and Guarro, 2014). Growth of C. albicans 202 
was inhibited at 0.125 µg/ml fluconazole and A. terreus was sensitive against voriconazole at 203 
a concentration of 0.25 µg/ml. Both, C. albicans and A. terreus tolerated bile, 204 
taurodeoxycholate and taurocholate (Fig. 2), but only bile conferred resistance against 205 
fluconazole for C. albicans and voriconazole in case of A. terreus. Taurocholate and 206 
taurodeoxycholate did not show a protective effect (Fig. 2). Therefore, protection against 207 
azoles appears specifically mediated by bile and - although a larger number of species and 208 
azoles need to be tested - this protection seems largely independent from the type of azole 209 
and the fungal species. 210 
 211 
3.3 Phospholipids in conjugated bile salt-mediated antifungal protection 212 
Lecithin (diacylphosphatidylcholine) is the major phospholipid in bile (Hay and Carey, 213 
1990). In a previous study we showed that an ethylacetate fraction of bile, mainly containing 214 
the lipid fraction of bile was by itself not sufficient for antifungal protection (Hsieh et al., 215 
2017). However, since phospholipids consist of a hydrophilic, zwitterionic phosphocholine 216 
head group and hydrophobic tails from the long fatty acyl chains (Hay and Carey, 1990), the 217 
phospholipid lecithin is likely to form mixed micelles with conjugated bile salts, which may 218 
increase the potency to encapsulate drugs. To test this assumption, we first analysed the effect 219 
of various lecithin concentrations on enhancement of the protective effect of taurocholate 220 
against caspofungin and amphotericin B (Fig. 3A). Here, we used a sub-protective 221 
concentration of 10 mg/ml of taurocholate at which C. albicans was sensitive against 2 µg/ml 222 
caspofungin and 4 µg/ml amphotericin B. Similarly, the phospholipid lecithin alone, in a 223 
concentration of up to 10 mM, was not protective. However, 2.5 mM of lecithin enhanced the 224 
protective effect of taurocholate and mediated caspofungin and amphotericin B resistance 225 
(Fig. 3A). Subsequently, the addition of phospholipids on fluconazole protection was 226 
analysed, whereby the protective effect with either taurocholate, taurodeoxycholate or bile 227 
was tested (Fig. 3B). Similar to bile, lecithin inhibited the hyphae inducing effect of 228 
taurocholate and taurodeoxycholate in RPMI medium (Hsieh et al., 2017). While this resulted 229 
in higher growth rates in the absence of drugs, up to 25 mM lecithin did not confer resistance 230 
against the azole. When we analysed the effect of the phospholipid lecithin on the critical 231 
concentration of taurocholate required to form micelles, the CMC value of taurocholate in the 232 
presence of lecithin did not significantly decrease in comparison to taurocholate alone (Fig. 233 
4). Therefore, we conclude that phospholipids are not facilitating micelle formation, but can 234 
enhance the protective effect of conjugated bile salts by forming mixed micelles. However, 235 
this combination does not protect from azoles and is not sufficient to resemble the protective 236 
effect of bile. 237 
 238 
3.4 Role of saturated fatty acids in antifungal protection 239 
The major proportion of free fatty acids in bile consists of saturated fatty acids (Chatterjee et 240 
al., 2007). Therefore, we investigated a possible contribution of saturated fatty acids towards 241 
antifungal protection. First, we studied growth of C. albicans in the presence of varying 242 
concentrations (range 0.1 – 3.2 mM) of saturated fatty acids of different chain length by 243 
simultaneously applying a fixed sub-protective concentration of 10 mg/ml taurocholate. As 244 
shown previously (Otzen et al., 2013), octanoic (C8) and decanoic (C10) acid exhibited a 245 
toxic effect towards C. albicans, which was not relieved by the presence of taurocholate. 246 
Propionate (C3) and butyrate (C4) were well tolerated in the concentrations applied, but due 247 
to their high water solubility are unlikely to contribute to micelle formation. No growth 248 
defect was observed by the addition of myristic (C14) and palmitic (C16) acid (Fig 5A). 249 
However, despite the presence of 10 mg/ml taurocholate, palmitic acid was not well 250 
solubilised and produced solid particles in the growth media at 37°C. Therefore, we 251 
investigated antifungal protection by the combination of myristic acid with taurocholate (Fig. 252 
5B). Indeed, when myristic acid exceeded a concentration of 0.8 mM (> 0.18 mg/ml) this 253 
mixture conferred resistance against caspofungin and amphotericin B. However, as with 254 
phospholipids, myristic acid did not confer resistance against fluconazole (not shown). 255 
Furthermore, similar to lecithin, a determination of the CMC value of taurocholate revealed 256 
that myristic acid did not significantly reduce the concentration of taurocholate required to 257 
form micelles (Fig. 4). Therefore, similar to phospholipids, saturated fatty acids reduce the 258 
concentration of taurocholate required to confer resistance against amphotericin B and 259 
caspofungin, but are not sufficient for protecting against azoles. 260 
 261 
3.5 Unsaturated fatty acids in antifungal protection 262 
Besides phospholipids and saturated fatty acids bile contains a significant proportion of 263 
unsaturated fatty acids, which is in agreement with a special importance of bile salts in 264 
solubilisation and uptake of essential fatty acids such as linolenic and arachidonic acid 265 
(Mullins et al., 1998). Fractionation of bile identified unsaturated fatty acids as playing a 266 
major role in repression of cholera toxin production in Vibrio cholera (Chatterjee et al., 2007; 267 
Plecha and Withey, 2015) and either bile, arachidonic or linoleic acid were shown to be 268 
effective in inhibiting binding of cholera toxin and Escherichia coli enterotoxin to the cell 269 
surface receptor GM1 (Chatterjee and Chowdhury, 2008). Therefore, we tested the effect of 270 
the polyunsaturated fatty acids arachidonic (20:4) and conjugated linolenic acid (18:3) on 271 
their protection from antifungals. A mixture of arachidonic and linolenic acid at a 272 
concentration of 0.2 or 0.8 mM of each compound was well tolerated by C. albicans, but 273 
failed to confer resistance against either amphotericin B (2 µg/ml, Fig. 6A) or fluconazole (in 274 
a range of 0.5 – 2 µg/ml, not shown). When added at concentrations above 0.8 mM, 275 
arachidonic acid, but not linolenic acid, inhibited growth of C. albicans. However, when 276 
combined with taurocholate even 1.6 mM of arachidonic acid was well tolerated. 277 
Furthermore, the mixture of arachidonic acid and linolenic acid (0.2 mM each) in 278 
combination with TC conferred resistance against amphotericin B and was also protective 279 
against up to 1 µg/ml fluconazole when polyunsaturated fatty acids were added with TC in a 280 
concentration of 0.8 mM of each unsaturated fatty acid (Fig. 6A and 6B). A single species of 281 
these polyunsaturated fatty acids was also able to confer resistance in a concentration 282 
dependent manner when combined with taurocholate. In these analyses, arachidonic acid 283 
showed a higher protective effect compared to linolenic acid. (Fig. 6C). In conclusion, while 284 
we cannot exclude an increased drug resistance by cell-wall reprogramming due to changes 285 
in the carbon source composition in the medium (Ene et al., 2012), mixed micelles formed 286 
from unsaturated fatty acids and conjugated bile salts increase the capability of taurocholate 287 
to encapsulate azole drugs. The results were further confirmed by investigating the effect of 288 
these polyunsaturated fatty acids on protection of A. terreus against voriconazole. While 289 
growth of A. terreus was slightly inhibited by a mixture taurocholate containing 0.8 mM of 290 
each unsaturated fatty acid, a protection against 0.25 and 0.5 µg/ml of voriconazole was 291 
observed (Fig. 6D). Unexpectedly, while neither phospholipids nor saturated fatty acids 292 
significantly decreased the CMC value, a significant decrease in the concentration of 293 
taurocholate required to form micelles was observed in the presence of the polyunsaturated 294 
fatty acids (Fig. 4). Therefore, these unsaturated fatty acids significantly contribute to the 295 
efficiency of bile to confer resistance against azole drugs. 296 
 297 
3.6 Protective effect of reconstituted synthetic bile 298 
Since all, phospholipids, saturated and unsaturated fatty acids showed some contribution in 299 
enhancement of antifungal protection by conjugated bile salts, we aimed in the reconstitution 300 
of a synthetic bile consisting of a mixture of taurocholate and taurodeoxycholate (30 mg/ml 301 
each), lecithin (5 mg/ml), myristic acid (10 mg/ml), arachidonic acid (2.5 mg/ml) and 302 
linolenic acid (2.5 mg/ml), resulting in a total of 80 mg solubilised solids in 1 ml of water. 303 
This mixture was compared to the protective effect of a mixture of taurocholate and 304 
taurodeoxycholate (30 mg/ml each) containing 2.5 mg/ml of each of the polyunsaturated fatty 305 
acids arachidonic and linolenic acid, resulting in a total of 65 mg/ml solubilised solids. These 306 
mixtures were compared with bile and a mixture of taurocholate and taurodeoxycholate for 307 
their concentration dependent protective effect against azoles and the highly water soluble 308 
antimetabolite flucytosine. Mixtures were adjusted in media to give a final concentration of 309 
10, 5, 2.5 and 0 mg/ml of total solubilised solids and 0.5 µg/ml of fluconazole was added to 310 
test resistance of C. albicans. While bile produced the highest cell density after 24 h of 311 
incubation, the complete mixture of all types of fatty acids with conjugated bile salts 312 
(reconstituted synthetic bile, RSB) as well as the polyunsaturated fatty acids in combination 313 
with conjugated bile salts were protective, but with slightly higher efficacy of the latter 314 
mixture compared to RSB (Fig. 7A). A mixture of the two conjugated bile salts alone did not 315 
protect against fluconazole in any of the concentrations tested. Similar to fluconazole 316 
resistance mediated towards C. albicans, the mixtures also conferred resistance of A. terreus 317 
against voriconazole with a comparable efficiency of all formulations except for the mixture 318 
only containing taurocholate and taurodeoxycholate that was not protective (Fig. 7B). This 319 
implied that polyunsaturated fatty acids added as additives are sufficient for the protective 320 
effect, whereas saturated fatty acids and phospholipids are mainly dispensable. Indeed, a 321 
determination of CMC values revealed that a mixture of arachidonic and linoleic acid in 322 
combination with unconjugated bile salts showed the same value as that determined for bile 323 
(Fig. 7C). In summary, these results indicate that reduction of the CMC by addition of 324 
polyunsaturated fatty acids appears as the main driving force to enhance the protection of 325 
conjugated bile salts against azoles. In contrast, when the same mixtures were tested for 326 
protection of C. albicans from flucytosine no protection was observed (Fig. 7D). Thus, 327 
similar to bile, mixed micelles of polyunsaturated fatty acids with conjugated bile salts are 328 
not able to inactivate small highly water soluble molecules. 329 
We finally compared bile, a mixture of conjugated bile salts and conjugated bile salts 330 
containing solubilised polyunsaturated fatty acids for inhibiting the influx of the model drug 331 
rhodamine 6G from C. albicans cells, which was measured by the time dependent increase of 332 
cellular fluorescence. Both, bile and conjugated bile salts with polyunsaturated fatty acids 333 
inhibited drug influx to a similar extent (Fig. 7E). This further confirms the essential 334 
contribution of polyunsaturated fatty acids to the high efficiency of bile to protect from 335 
antifungals.  336 
 337 
4. Discussion 338 
Previous studies have shown that C. albicans persists under antifungal therapy in the gall 339 
bladder of mice (Jacobsen et al., 2014). This protection is mediated by bile and conjugated 340 
bile salts that trap antifungals in micelles (Hsieh et al., 2017). However, it remained unclear, 341 
by which mechanism bile, but not conjugated bile salts can protect from azoles. Here, we 342 
discovered that polyunsaturated fatty acids, which are normal constituents of bile are 343 
responsible for mediating this higher protective efficiency of bile compared to conjugated 344 
bile salts. Moreover, we also found that antifungal protection is not limited to C. albicans, but 345 
also protects other pathogenic fungi, and probably pathogenic microorganisms in general 346 
from therapeutic drugs. In this respect, a preliminary analysis revealed that bile and 347 
reconstituted bile containing polyunsaturated fatty acids conferred increased resistance of E. 348 
coli against kanamycin, whereby ampicillin remained active (data not shown).  349 
The increase of the protective effect of polyunsaturated fatty acids and especially that of 350 
arachidonic acid was surprising, taking into account previous investigations that revealed 351 
increased antifungal drug sensitivity of C. albicans when cultivated in presence of 352 
arachidonic acid (Ells et al., 2009; Mishra et al., 2014). Incorporation of arachidonic acid into 353 
the fungal cell membrane provokes an increase in the production of ergosterol and is 354 
accompanied by increased membrane fluidity. Although arachidonic acid does not reduce cell 355 
viability, this membrane modulation appears to increase susceptibility against antifungals 356 
(Ells et al., 2009). Integration of polyunsaturated fatty acids also occurs when C. albicans is 357 
grown in bile as confirmed by analyses of bile-grown C. albicans. Under these conditions cell 358 
membranes revealed an integration of arachidonic and linolenic acid (data not shown). 359 
Furthermore, in agreement with previous studies, neither of these polyunsaturated fatty acids 360 
protected against antifungals (Fig. 6A) when used in the absence of conjugated bile salts. 361 
The capacity of conjugated bile salts to solubilise polyunsaturated fatty acids is larger than 362 
that for monounsaturated or saturated fatty acids (Smith and Lough, 1976). Thereby, 363 
compared to monounsaturated or saturated fatty acids, polyunsaturated fatty acids efficiently 364 
lower the CMC value of glycodeoxycholate (Freeman, 1969). Therefore it can be concluded 365 
that arachidonic and linolenic acid increase the efficiency of conjugated bile salts to form 366 
micelles, which is obviously accompanied by a greater capability to trap antifungals in these 367 
mixed micelles as shown by the reduction of the bioavailability of azole drugs and the high 368 
efficiency in preventing rhodamine 6G influx. 369 
Orthotopic liver transplantation produces a significant risk factor for patients to acquire 370 
invasive fungal infections with Aspergillus and Candida species as main causative agents 371 
(Pacholczyk et al., 2011; Salavert, 2008). Prophylactic therapy in these patients with polyene 372 
macrolides, echinocandins or azoles may decrease the risk for invasive fungal infections as 373 
these antifungals may prevent fungal dissemination and establishment of disease outside of 374 
the biliary system (Liu et al., 2011). However, our study indicates that these drugs appear 375 
ineffective in clearing infections that persist within the gall bladder, biliary duct or even in 376 
the intestine, as bile efficiently reduces their bioavailability. 377 
In conclusion, it should be considered to test the efficacy of antifungals in the presence of 378 
bile or a mixture of polyunsaturated fatty acids with conjugated bile salts. Drugs that remain 379 
active under these conditions as shown here for flucytosine might act as more suitable 380 
compounds for prophylactic therapy in high risk patients. 381 
 382 
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Figure legends 470 
 471 
Figure 1: Analysis of amphotericin B sensitivity of various fungal species in the presence 472 
of conjugated bile salts. (A) Resistance of C. glabrata and S. cerevisiae against 0.5 µg/ml 473 
amphotericin B. Cells were incubated at 37°C in RPMI medium with or without 25 mg/ml 474 
taurocholate (TC). End point OD600 was taken for C. glabrata after 20 h and for S. cerevisiae 475 
after 45 h. (B) Resistance of A. fumigatus and A. terreus against 1.0 µg/ml amphotericin B. 476 
Cells were incubated at 37°C in RPMI medium with or without 25 mg/ml TC. End point 477 
OD600 was taken after 20 h. (C) Resistance of C. neoformans strain H99 and 1841 against 2.0 478 
µg/ml amphotericin B. Cells were incubated at 30°C in YPD medium with or without 25 479 
mg/ml TC and end points were measured after 20 h. (C). The bar diagrams show mean + SD 480 
from three independent experiments in technical duplicates. Data were analysed by ANOVA 481 
followed by Tukey's multiple comparison (***p < 0.005). Taurocholate confers resistance 482 
against amphotericin B in all species tested. 483 
 484 
Figure 2: Protection of bile and conjugated bile salts against azoles. Fungi were incubated 485 
at 37°C in RPMI medium supplemented with either 25 mg/ml taurocholate (TC), 12.5 mg/ml 486 
taurodeoxycholate (TDC) or 12.5 mg/ml bile and OD600 was taken after 20 h of growth. (A) 487 
Resistance of C. albicans against various concentrations of fluconazole. (B) Resistance of A. 488 
terreus against various concentrations of voriconazole. Results are shown as mean + SD from 489 
three independent experiments in technical duplicates. Statistical analyses were performed by 490 
ANOVA followed by Tukey's multiple comparison (***p < 0.005). Only bile confers 491 
resistance against azole treatment. 492 
 493 
Figure 3: Analysis of the effect of phospholipids on antifungal resistance. (A) YPD 494 
medium was supplemented with various concentrations of phospholipids (PL, lecithin) with 495 
or without 10 mg/ml taurocholate (TC, sub-protective at this concentration) and resistance of 496 
C. albicans against amphotericin B (AMB; 4 µg/ml) and caspofungin (CAS; 2 µg/ml) was 497 
studied. Growth was evaluated after 20 h incubation at 37°C. Addition of phospholipids (in 498 
the form of lecithin) increased the efficacy of TC to protect from both drugs. (B) Protective 499 
effect of 25 mM PLs with or without 12.5 mg/ml TC or taurodeoxycholate (TDC) on C. 500 
albicans cultivated in the presence of various fluconazole concentrations. PLs do not mediate 501 
fluconazole resistance. Data are shown as mean + SD from three independent experiments in 502 
technical triplicates. Statistical analyses were performed by ANOVA followed by Tukey's 503 
multiple comparison (***p < 0.005; NS = not significant). 504 
 505 
Figure 4: Effects of lipid components on critical micelle concentrations of taurocholate. 506 
Taurocholate (10 mg/ml; TC) was mixed with either 10 mM phospholipids (PL), 1.6 mM 507 
myristic acid (C14) or an equal mixture of arachidonic (AA; 0.2 or 0.8 mM) and conjugated 508 
linolenic acid (CLA; 0.2 or 0.8 mM). The critical micelle concentration (CMC) was 509 
determined from serial dilutions in the presence of Eosin Y. Data represent mean + SD from 510 
two independent experiments. (***P < 0.005, NS = not significant). Statistical significance 511 
was calculated by ANOVA followed by Tukey's multiple comparison. 512 
 513 
Figure 5: Role of saturated fatty acids in antifungal protection. C3 = propionic acid, C4 = 514 
butyric acid, C8 = caprylic acid, C10 = decanoic acid, C14 = myristic acid, C16 = palmitic 515 
acid. In all analyses YPD medium supplemented with 10 mg/ml taurocholate (TC) was used. 516 
C. albicans cells were grown at 37°C and optical density (OD600) was determined after 20 h. 517 
(A) Effect of various fatty acids in combination with TC on growth of C. albicans. C8 and 518 
C10 provoke toxic effects that are not compensated by TC. (B) Protective effect of different 519 
C14 concentrations in presence of TC on caspofungin (CAS; 2 µg/ml) and amphotericin B 520 
(AMB; 4µg/ml) resistance. At least 0.8 mM myristic acid are required for increasing the 521 
protective effect of TC. Bar diagrams show mean values + SD from three independent assays 522 
measured in duplicates. Data were analysed by ANOVA followed by Tukey's multiple 523 
comparison (***p < 0.005). 524 
 525 
Figure 6: Contribution of polyunsaturated fatty acids on antifungal protection of 526 
conjugated bile salts. Analyses on C. albicans were performed in YPD medium. Resistance 527 
of A. terreus was tested in RPMI medium. Taurocholate (TC) was used in a concentration of 528 
10 mg/ml. (A) Sensitivity of C. albicans against amphotericin B (AMB; 2 µg/ml). 529 
Arachidonic acid (AA; 0.2 mM; 0.06 mg/ml) and conjugated linolenic acid (CLA; 0.2 mM; 530 
0.056 mg/ml) were added in equal concentration. (B) Fluconazole protection of C. albicans 531 
by addition of equal amounts of AA (0.8 mM; 0.244 mg/ml) and CLA (0.8 mM; 0.222 mg/ml) 532 
to TC containing media. (C) Protection of C. albicans against fluconazole (1 µg/ml) by 533 
addition of different concentrations of either AA or CLA. (D). Voriconazole protection of A. 534 
terreus by addition of equal amounts of AA (0.8 mM; 0.244 mg/ml) and CLA (0.8 mM; 0.222 535 
mg/ml) to TC containing media. Data were statistically analysed by ANOVA followed by 536 
Tukey's multiple comparison (***p < 0.005, **p < 0.01). Data represent mean values + SD 537 
from three individual replicates in technical triplicates. 538 
 539 
Figure 7: Antifungal protection by reconstituted bile formulations. RSB = reconstituted 540 
synthetic bile ( 30 mg/ml taurocholate (TC), 30 mg/ml taurodeoxycholate (TDC), 5 mg/ml 541 
lecithin, 10 mg/ml myristic acid, 2.5/ml mg arachidonic acid (AA) and 2.5 mg/ml conjugated 542 
linolenic acid (CLA)); TDC + TC = 30 mg/ml of each compound; TDC + TC + AA + CLA = 543 
30 mg/ml of each conjugated bile salt with 2.5 mg/ml of each polyunsaturated fatty acid. All 544 
solutions were diluted to the respective concentration of solubilised solids as indicated on the 545 
x-axis of the respective panels. (A) Comparison of C. albicans fluconazole (0.5 µg/ml) 546 
protection. Bile supports growth at a significantly higher level than RSB and the TDC + TC 547 
=AA + CLA mixtures. Only the mixture of TDC + TC does not protect. (B) Voriconazole (1 548 
µg/ml) protection of A. terreus. TDC + TC are not protective. No significant difference in the 549 
protection efficacy is observed with the other mixtures compared to bile. (C) Comparison of 550 
critical micelle concentrations of bile, TDC + TC and TDC +TC + AA +CLA. (D) Protection 551 
of C. albicans against flucytosine (4 µg/ml). No protective effect is observed. (E) Rhodamine 552 
6G (R6G) influx assay of C. albicans cultivated in the presence of 1 µM R6G in RPMI 553 
medium supplemented with 1 mg/ml of bile or reconstituted bile formulations. RPMI 554 
medium with R6G but without other supplements served as control. All data represent mean 555 
values + SD from at least two independent experiments and measured from technical 556 
duplicates. Statistical analyses were performed by ANOVA followed by Tukey's multiple 557 
comparison (***p < 0.005, **p < 0.01, NS, = not significant). 558 
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